Literature DB >> 31112312

Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint.

E Manojlovic-Gacic1, J Bollerslev2,3, O Casar-Borota4,5.   

Abstract

Neuroendocrine tumours of the adenohypophysis have traditionally been designated as pituitary adenomas to underline their usually indolent growth and lack of metastatic potential. However, they may demonstrate a huge spectrum of growth patterns and endocrine disturbances, some of them significantly affecting health and quality of life. To predict tumour growth, risk of postoperative recurrence and response to medical therapy in patients with pituitary neuroendocrine tumours is challenging. A thorough histopathological and immunohistochemical diagnostic work-up is an obligatory part of a multidisciplinary effort to precisely define the tumour type and assess prognostic and predictive factors on an individual basis. In this review, we have summarized the current status in the pathology in pituitary neuroendocrine tumours based on the selection of references from the PubMed database. We have presented possible diagnostic approaches according to the current pituitary cell lineage-based classification. The importance of recognizing histological subtypes with potentially aggressive behaviour and identification of prognostic and predictive tissue biomarkers have been highlighted. Controversies related to particular subtypes of pituitary tumours and a still limited prognostic impact of the current classification indicate the need for further refinement. Multidisciplinary approach including clinical, pathological and molecular genetic characterization will be essential for improved personalized therapy and the search for novel therapeutic targets in patients with pituitary neuroendocrine tumours.
© 2019 British Neuropathological Society.

Entities:  

Keywords:  diagnostic approach; pituitary adenoma; pituitary neuroendocrine tumour; predictive markers; prognostic markers; transcription factors

Mesh:

Year:  2019        PMID: 31112312     DOI: 10.1111/nan.12568

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  8 in total

1.  Endoscopic vs. microscopic transsphenoidal surgery outcomes in 514 nonfunctioning pituitary adenoma cases.

Authors:  Shuaihua Song; Linping Wang; Qianjin Qi; Haoran Wang; Li Feng
Journal:  Neurosurg Rev       Date:  2022-03-01       Impact factor: 3.042

Review 2.  Overview of the 2022 WHO Classification of Pituitary Tumors.

Authors:  Sylvia L Asa; Ozgur Mete; Arie Perry; Robert Y Osamura
Journal:  Endocr Pathol       Date:  2022-03-15       Impact factor: 3.943

Review 3.  Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.

Authors:  Ashley B Grossman; Shereen Ezzat; Sylvia L Asa; Ozgur Mete; Michael D Cusimano; Ian E McCutcheon; Arie Perry; Shozo Yamada; Hiroshi Nishioka; Olivera Casar-Borota; Silvia Uccella; Stefano La Rosa
Journal:  Mod Pathol       Date:  2021-05-21       Impact factor: 7.842

4.  Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.

Authors:  John P Andrews; Rushikesh S Joshi; Matheus P Pereira; Taemin Oh; Alexander F Haddad; Kaitlyn M Pereira; Robert C Osorio; Kevin C Donohue; Zain Peeran; Sweta Sudhir; Saket Jain; Angad Beniwal; Ashley S Chopra; Narpal S Sandhu; Tarik Tihan; Lewis Blevins; Manish K Aghi
Journal:  World Neurosurg       Date:  2021-04-20       Impact factor: 2.210

5.  Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.

Authors:  Olivera Casar-Borota; Fredrik Pontén; Abdellah Tebani; Jelena Jotanovic; Neda Hekmati; Åsa Sivertsson; Olafur Gudjonsson; Britt Edén Engström; Johan Wikström; Mathias Uhlèn
Journal:  Acta Neuropathol Commun       Date:  2021-11-10       Impact factor: 7.801

Review 6.  Architects of Pituitary Tumour Growth.

Authors:  Maria Eugenia Sabatino; Ezequiel Grondona; Ana Lucía De Paul
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

7.  Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway.

Authors:  Richard A Hickman; Jeffrey N Bruce; Marc Otten; Alexander G Khandji; Xena E Flowers; Markus Siegelin; Beatriz Lopes; Phyllis L Faust; Pamela U Freda
Journal:  Neuropathol Appl Neurobiol       Date:  2020-12-20       Impact factor: 8.090

8.  Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification.

Authors:  Jiayu Liu; Yuhao He; Xuebin Zhang; Xiaoling Yan; Ying Huang
Journal:  Oncol Lett       Date:  2020-01-08       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.